Navigation Links
Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Date:12/5/2012

ted therapy ineffective.  The authors concluded that in this study the combination of brostallicin and cisplatin showed promising activity in heavily pretreated metastatic triple-negative breast cancer patients and achieved its primary endpoint comparing favorably to other Phase 2 clinical trials in this disease.  Final results of this trial are expected to be presented at the American Society of Clinical Oncology 2013 Annual Meeting. A follow-up randomized Phase 2 trial is in development.

About Triple-negative Breast Cancer

This term is used to describe breast cancers (usually invasive ductal carcinomas) whose cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces. Breast cancers with these characteristics tend to occur more often in younger women and in African-American women. Triple-negative breast cancers tend to grow and spread more quickly than most other types of breast cancer. Because the tumor cells lack these certain receptors, neither hormone therapy nor drugs that target HER2 are effective treatments (but chemotherapy can still be useful if needed). About 10% to 20% of breast cancers are triple negative.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies.

About Cell Therapeutics, Inc.

Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making canc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
4. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
5. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
6. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
7. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
8. Alzheimers Therapeutics Reviewed by NeuroPerspective
9. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... CHAPEL HILL, N.C., Oct. 7 Seasoned ... dynamic new set of natural,treatment techniques that are ... such as pain, stress, anxiety, phobias, weight,loss, and ... (PTSD).,Known as "Energy Psychology" (and crossing over into ...
... for Fourth Consecutive Year, INDIANAPOLIS, Oct. ... of the magazine,s Top 500 innovative users ... handful of companies in the biotech,and pharmaceutical ... 86, in the 2008 report,outperformed others in ...
... CARLOS, Calif., Oct. 7 Nektar,Therapeutics (Nasdaq: NKTR ... present at the upcoming Natixis Bleichroeder Second Annual Hidden ... Monday, October 13,2008 at 2:30 p.m. ET., The ... posted,on the Investor Relations, Events Calendar section of the ...
Cached Biology Technology:Upcoming 'Energy Psychology' Event - New Breakthrough 'Do It Yourself' Healing 2InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List 2
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... awarded Michael F. Holick, PhD, MD, of Boston University ... Avioli Award. Holick, a professor of medicine, physiology and ... understanding of vitamin D and its role in disease ... the American Society for Bone and Mineral Research (ASBMR) ... It is named for ASBMR,s first president and founding ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... Heart Institute at Intermountain Medical Center have developed a ... cardiologists the ability to see the precise source of ... a condition that affects nearly three million Americans. ... of the heart three dimensionally significantly improves the chances ...
... three are historically recognized as due to plague, but ... 21st centuries AD there were microbiological evidences that the ... "For a long time scholars from different disciplines have ... past pandemics. Only ancient DNA analyses carried out on ...
... May 9, 2013 Wexford Science & Technology, LLC, ... Wake Forest Innovation Quarter , today announced that ... underway represents an additional $150 million investment in downtown ... investment in the Innovation Quarter to more than $250 ...
Cached Biology News:Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation 2Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation 3Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3
... anti-phospho-IRS1 (Tyr896) ... to amino acid region encompassing ... phospho-IRS1 (Tyr896). ... Quality Assurance: ...
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Biology Products: